Morgenstern H, Glazer W M, Niedzwiecki D, Nourjah P
Am J Public Health. 1987 Jun;77(6):717-24. doi: 10.2105/ajph.77.6.717.
To quantify the impact of chronic exposure to neuroleptic medication on the occurrence of tardive dyskinesia (TD), we conducted a meta-analysis of data collected from 21 studies published between 1966 and 1985. The observed prevalence of dyskinesia was greater among exposed subjects in all 21 studies; we estimate that, on the average, the occurrence rate was 2.9 times greater in exposed persons than would be expected if they had been unexposed. We estimate that 65 per cent of exposed cases and 51 per cent of all cases in these investigations were caused by long-term neuroleptic exposure. Among adult United States residents in 1980, we estimate that there were approximately 193,000 neuroleptic-induced TD cases of which about 60 per cent occurred in outpatients. We also observed substantial heterogeneity of effect (rate ratio) across studies, however, partially explained, by changes and differences in the rate of dyskinesia, by differences in the frequency of certain effect modifiers, and by differences in diagnostic methods. Methodologic limitations of the studies and their possible effects on our results are discussed.
为了量化长期接触抗精神病药物对迟发性运动障碍(TD)发生的影响,我们对1966年至1985年间发表的21项研究收集的数据进行了荟萃分析。在所有21项研究中,接触药物的受试者中观察到的运动障碍患病率更高;我们估计,平均而言,接触者的发生率比未接触者预期的发生率高2.9倍。我们估计,在这些调查中,65%的接触病例和51%的所有病例是由长期接触抗精神病药物引起的。在1980年的美国成年居民中,我们估计大约有193,000例抗精神病药物引起的TD病例,其中约60%发生在门诊患者中。然而,我们也观察到不同研究之间效应(率比)存在很大异质性,部分原因是运动障碍发生率的变化和差异、某些效应修饰因素频率的差异以及诊断方法的差异。讨论了这些研究的方法学局限性及其对我们结果可能产生的影响。